DLBCL-derived EVs can carry carbonic anhydrase 1 (CA1) that fosters resistance to standard R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone, with rituximab) therapy[30]. Here, CA1 is linked to diffuse large B-cell lymphoma.